
|Videos|May 31, 2017
Considerations Following Locoregional Therapy in HCC
Considerations Following Locoregional Therapy in HCC
Advertisement
May 2015
- 64-year old obese female presented with fatigue and unexplained weight loss
- History of nonalcoholic fatty liver disease (NAFLD), then nonalcoholic steatohepatitis (NASH)
- Lab results: AFP= 1,500 IU/ml
- ECOG=1; Child-Pugh A
- CT revealed 1 large liver mass, right side of liver close to a major blood vessel
- No extrahepatic disease
- Liver-directed therapy with DEB-TACE was performed
- Patient reported abdominal pain following DEB-TACE and required analgesics; low-grade fever
- Patient had a complete response
- AFP= 200 IU/ml at follow up
February 2017
- Follow-up imaging showed progression and evidence of bone metastases
- Therapy was initiated with sorafenib at 400 mg BID
- Follow-up testing showed liver decompensation
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5




















